

June 8, 2011  
Nobelpharma Co., Ltd.

Notification of Start of Phase III Trial of Drug for Apnea of Prematurity

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President: Jin Shiomura) has begun Phase III trials of a drug to treat apnea of prematurity (effective ingredient: caffeine citrate; development code: NPC-11; referred to herein as “the drug”).

The drug has been approved in the US, EMA (by 29 countries including UK and France), Australia and others, where it is used as the primary choice for treatment of apnea of prematurity.

Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Tokyo; President: Gerrard McKenna; referred to herein as “NBI”) was requested of the development for this drug on May 21, 2010 from the Ministry of Health, Labour and Welfare based on the examination of its Committee to Examine Unapproved High Medical Need and Off-label Drugs. Nobelpharma has contracted with NBI for joint development of the drug.

Please direct inquiries to:  
Tsutomu Sugaya, Executive Officer and  
Head of Administrative Affairs and Corporate Planning  
Nobelpharma Co., Ltd.  
12-10 Nihonbashi-kobunacho, Chuo-ku, Tokyo, 103-0024  
Tel: 03-5651-1160